Skip to main content
. Author manuscript; available in PMC: 2011 Mar 29.
Published in final edited form as: Curr Oncol Rep. 2009 Sep;11(5):346–352. doi: 10.1007/s11912-009-0047-x

Figure 1.

Figure 1

The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) cascade in acute myeloid leukemia, and relevant targeted therapies. BAD—bcl-2 antagonist of cell death; CDK2—cyclin-dependent kinase 2; EGFR—epidermal growth factor receptor; PDK1—phosphoinositide-dependent kinase 1; PIP2—phosphatidylinositol-4,5-bisphosphate; PIP3—phosphatidylinositol-3,4,5-trisphos phate; TSC1, TSC2—tuberous sclerosis proteins 1 and 2; VEGF—vascular endothelial growth factor.